SignalXSignalX

AARD Aardvark Therapeutics, Inc.

8-K Current Report
Filed: February 27, 2026
Health Care
Pharmaceutical Preparations
Aardvark Therapeutics, Inc. Overview

Aardvark Therapeutics, Inc. (AARD) 8-K current report filed with SEC EDGAR on February 27, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

  • • Voluntary pause of Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome hyperphagia — a major clinical setback
  • • Trial suspension signals potential safety signal, enrollment issue, or regulatory concern; reason not disclosed in Item 8.01
+2 more insights

Get deeper insights on Aardvark Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.